Navigation Links
ResMed VPAP III ST

ProductsResMed VPAP III ST
Company ResMed Corp
Item ResMed VPAP III ST
Features 
  • Uses same device platform as the AutoSet SpiritTM, AutoSet RespondTM and S7TM series of devices for lower inventory, training and labor costs
  • Available with optional integrated humidification
  • VsyncTM algorithm maintains reliable breath triggering and cycling performance to ensure that patients do not feel "out-of-sync with their VPAP, even when normal leaks occur.
  • IPAP MaxTM feature offers customizable maximum allowable inspiratory time to protect patients from prolonged inspiratory times related to mask or mouth leak. This helps avoid increased work of breathing and arousals, which means better treatment and fewer patient complaints and callbacks.
  • IPAP MinTM feature helps eliminate shortened inspiratory times often seen in restrictive patients, such as ALS and post-polio patients, and protects them from becoming under- ventilated and waking up gasping for air.
  • Software-controlled, variable-speed motor technology and rise time settings provide more comfortable pressure and flow profiles for better treatment tolerance, resulting in improved patient comfort and compliance with less effort and fewer callbacks.
  • The VPAP III offers a range of tools to meet immediate and long-term data management needs. Both treatment effectiveness and usage data are available on the LCD and with download and viewing in AutoScanTM software.
  • Choice of CPAP, Spontaneous, Spontaneous/Timed and Timed Treatment Modes
Description The VPAP III ST is a complete system solution for SDB, providing comfortable and effective bilevel treatment with additional treatment modes. The VPAP III ST is an effective business solution for clinicians, HMEs and sleep labs.
Info ResMed Corp
Customer Service: (800) 424-0737
Web site: http://www.resmed.com/

Related medicine products :

1. ResMed S8 Elite
2. ResMed S7 Elite CPAP
3. ResMed S7™ Lightweight CPAP Device
4. ResMed S8 Escape
5. ResMed AutoSet Spirit
6. ResMed AutoSet Respond
7. ResMed S8 AutoSet Vantage
8. ResMed VPAP III
9. ResMed VPAP III ST-A
...er offers a wide range of fixed curve catheters de...hildren and other patients with small anatomies. E...tions using only the finest materials. A unique mu...iding and extrusion technologies results in the ex...
The Mayfield Triad Skull Clamp, compatible with the full line of Mayfield products, gives visual indication of clamping force on all three skull pins and also provides the user with the possibility o
A fully automated, benchtop instrument designed for high-volume urine testing, using Siemens' proven technology in dry-pad urine chemistry analysis.
PocketChem UA is the first hand-held urine analyzer so it doesnt take up valuable lab bench space. Automation of urine analysis can minimize the variability in results between operators and transcrip
Medicine Products:
(Date:12/2/2008)... -- Today, the University HealthSystem,Consortium...een appointed Vice,President, Quality and Patient... year and a half as director of quality and infect...Chicago, Ill. Previously, she was the senior dire..., "Julie,s experience at Northwestern has r...
(Date:12/2/2008)...USNewswire/ -- A scientist who helped,explain how...of information we,see has won the 2009 Universit..., Anne Treisman, the James S. McDonnell Disting...nceton University , was selected for the ninth Gra...s. , Treisman, a cognitive psychologist, pr...
(Date:12/2/2008)...es have substantially higher rates of mental healt...to results from a systematic review and meta-analy...arching for studies over the past four decades con... in homeless people, Seena Fazel and colleagues of...volving 5,684 homeless individuals based in the US...
(Date:12/2/2008)...University, The Brigham and Women,s Hospital (Bost...als has found a new drug with the potential to all... work. , Dr Shantha Rajaratnam from Monash Univ...hological Medicine said tasimelteon, a drug which ... a highly effective treatment for circadian rhythm...
Breaking Medicine News(10 mins):Health News:Julie Cerese Returns to University HealthSystem Consortium as Vice President of Quality and Patient Safety 2Health News:Theory of How Brain Builds Images Earns Grawemeyer Prize 2Health News:New medication brings hope of jet lag cure 2
...d blood disorder that affects red blood cells. Peo...that contain an abnormal type of hemoglobin. Somet...d have difficulty passing through small blood vess... obstruct blood vessels, the result is often pain ...
...dliest of cancers, affecting many people a year an...c cancer is the most aggressive cancer and there a...ged attack, researchers were able to destroy deadl...tube and in lab animals. // The work was led by D...
...dely used anticancer drug, hydroxyurea, shows pote...and in mice, according to researchers. The new com...nt of these tumors. // Previous drugs derived fro... blocking the same cell targets as hydroxyurea, bu...
...evers commonly used to counter the pain and inflam...sk of getting Alzheimer's disease. In addition to ... to selectively reduce levels of a harmful protein...dy developed from research suggesting that people ...
Other Medicine News:
(Date:11/25/2008)...ts against expanding statin use broadly in wake of..., Nov. 25 JUPITER, a clinical tria...ular risk of healthy patients with elevated CRP, s...lts, according to a national poll directed at heal...t in the online poll conducted by medical news sit...
(Date:11/25/2008)...Nov. 25 Poniard,Pharmac...cal company focused on,innovative oncology therap...rategic alternatives for its preclinical research ...ts resources on the clinical development of picopl...the initial commercialization of,picoplatin in th...
(Date:11/25/2008)...ical Trial to Assess Survival of Patients Receivin...ectable Hepatocellular Carcinoma , , BELLEV...Oncology, Inc. (LSO) today announced the completio... of Light Infusion Therapy(TM) (Litx(TM)) as a tre...HCC), also known as hepatoma or primary liver canc...
(Date:11/24/2008)...apan, Nov. 24 Takeda Pharmaceutica... Takeda Global Research & Development Center, ...isory Committee of the U.S. Food and Drug Administ...xostat for the treatment of hyperuricemia in pati...f approval, with one panel member abstaining. The ...
Breaking Medicine Technology:Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3BIO key 28R 29 Receives New Mobile Data Contract Award From Indiana Police Agency 2970 1BIO key 28R 29 Receives New Mobile Data Contract Award From Indiana Police Agency 2970 2BIO key 28R 29 Receives New Mobile Data Contract Award From Indiana Police Agency 2970 3Nanoemulsion vaccines show increasing promise 4716 1Nanoemulsion vaccines show increasing promise 4716 2Nanoemulsion vaccines show increasing promise 4716 3Nanoemulsion vaccines show increasing promise 4716 4International health experts to enlist the public in war on African malaria 17256 1International health experts to enlist the public in war on African malaria 17256 2International health experts to enlist the public in war on African malaria 17256 3International health experts to enlist the public in war on African malaria 17256 4International health experts to enlist the public in war on African malaria 17256 5International health experts to enlist the public in war on African malaria 17256 6International health experts to enlist the public in war on African malaria 17256 7International health experts to enlist the public in war on African malaria 17256 8Genetic variant mimics effect of heart failure medications 2963 1Genetic variant mimics effect of heart failure medications 2963 2Genetic variant mimics effect of heart failure medications 2963 3Genetic variant mimics effect of heart failure medications 2963 4
...BRIDGE, Mass.--(BUSINESS WIRE)--Jun 26, 2007 - Sir...armaceutical company,focused on discovering and de... aging, announced today that activation of SIRT1, ...wn to protect,against neurodegenerative diseases s... Sclerosis in animal models. These findings,appear...
...THESDA, Md., June 26, 2007 /PRNewswire-FirstCall/ ...cusing on the development of,novel, proprietary an... autoimmune diseases, announced that a study publi...cademy of Sciences (1) supports,the findings of se...sed as the target for Micromet,s product candidate...
Other Medicine Technology:Resveratrol Studies Suggest Broad Implications for SIRT1 Activation,in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease 2Resveratrol Studies Suggest Broad Implications for SIRT1 Activation,in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease 3Publication Confirms that EpCAM, the Target for Two of Micromet's,Product Candidates, Is Overexpressed on Cancer Stem Cells of,Certain Cancers 2Publication Confirms that EpCAM, the Target for Two of Micromet's,Product Candidates, Is Overexpressed on Cancer Stem Cells of,Certain Cancers 3Publication Confirms that EpCAM, the Target for Two of Micromet's,Product Candidates, Is Overexpressed on Cancer Stem Cells of,Certain Cancers 4